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ABSTRACT
Background Cysteine- altering NOTCH3 variants 
identical to those causing the rare monogenic 
form of stroke, CADASIL (cerebral autosomal 
dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy), have been reported more 
common than expected in the general population, but 
their clinical significance and contribution to stroke and 
dementia risk in the community remain unclear.
Methods Cysteine- altering NOTCH3 variants were 
identified in UK Biobank whole- exome sequencing data 
(N=200 632). Frequency of stroke, vascular dementia 
and other clinical features of CADASIL, and MRI white 
matter hyperintensity volume were compared between 
variant carriers and non- carriers. MRIs from those with 
variants were visually rated, each matched with three 
controls.
Results Of 200 632 participants with exome 
sequencing data available, 443 (~1 in 450) carried 
67 different cysteine- altering NOTCH3 variants. 
After adjustment for various covariates, NOTCH3 
variant carriers had increased risk of stroke (OR: 
2.33, p=0.0004) and vascular dementia (OR: 5.00, 
p=0.007), and increased white matter hyperintensity 
volume (standardised difference: 0.52, p<0.001) and 
white matter ultrastructural damage on diffusion MRI 
(standardised difference: 0.72, p<0.001). On visual 
analysis of MRIs from 47 carriers and 148 matched 
controls, variants were associated with presence of 
lacunes (OR: 5.97, p<0.001) and cerebral microbleeds 
(OR: 4.38, p<0.001). White matter hyperintensity 
prevalence was most increased in the anterior temporal 
lobes (OR: 7.65, p<0.001) and external capsule (OR: 
13.32, p<0.001).
Conclusions Cysteine- changing NOTCH3 variants are 
more common in the general population than expected 
from CADASIL prevalence and are risk factors for 
apparently ’sporadic’ stroke and vascular dementia. They 
are associated with MRI changes of small vessel disease, 
in a distribution similar to that seen in CADASIL.
INTRODUCTION
Cerebral small vessel disease (SVD) is a major cause 
of stroke and dementia.1 2 Most cases are sporadic, 
although polygenic risk factors appear important.3 
SVD is the most common type of ischaemic stroke 
caused by single- gene disorders; the most common 
is cerebral autosomal dominant arteriopathy with 
subcortical infarcts and leukoencephalopathy 
(CADASIL), which results in early- onset lacunar 
stroke and dementia, and is caused by distinctive 
NOTCH3 variants that lead to an extra unpaired 
cysteine residue in one of 34 epidermal growth 
factor- like repeat (EGFR) domains.4
Although CADASIL is considered rare, with a 
reported disease prevalence of 4 per 100 000,5 6 a 
much higher frequency of typical cysteine- altering 
NOTCH3 variants was reported as 1 in 400 indi-
viduals.7 8 These could contribute to the risk of 
apparently sporadic lacunar stroke, but the clinical 
significance of these variants remains uncertain. 
Studies have mostly been conducted on anonymised 
genome- sequencing databases,7 and it is unclear 
whether such apparently ‘asymptomatic’ variants 
have clinical implications.9 It has been demon-
strated that such variants are more likely to be in 
EGFR domains 7–34, while variants within clinical 
CADASIL cases are more likely, although not exclu-
sively, in domains 1–6.10
To determine whether these variants increase 
disease, analysis of sequencing databases in which 
clinical data are also available is required. We used 
whole- exome sequence data from 200 632 partic-
ipants in UK Biobank to determine the frequency 
of NOTCH3 variants, and whether they were asso-
ciated with stroke and dementia. Moreover, in the 
subset of individuals in whom MRI scanning was 
performed, we correlated presence of NOTCH3 
variants with MRI markers of SVD including 
white matter hyperintensities (WMHs) and lacunar 
infarcts and determined whether variant carriers 
had a similar spatial distribution of lesions to 
that seen in typical CADASIL cases. This study 
extends previous studies, particularly the Geisinger 
DiscovEHR cohort,8 with a larger sample size 
providing greater power to examine associations 
with the risk of both stroke and dementia.
METHODS
Study population
UK Biobank is a prospective study of over 500 
000 healthy volunteers aged 40–69 years recruited 
across the UK between 2006 and 2010.11 About 9 
million individuals were invited to join, of whom 
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5.5% participated in the baseline assessment.12 Phenotypic data 
were collected through questionnaires and physical examina-
tions. A subset of 100 000 individuals are also participating in the 
MRI Study, and approximately 40 000 brain MRIs were avail-
able at the time of this analysis. These participants were selected 
on the basis of travelling distance from the imaging centre and 
not clinical information. All MRIs were performed on one of 
the two identical Skyra 3.0T scanners (Siemens Medical Solu-
tions, Germany). Identical acquisition parameters and quality 
control was used for all scans.13 In October 2020, whole- exome 
sequences of 200 632 UK Biobank participants were released 
and all were included here. This analysis was performed under 
UK Biobank application number 36509.
Ascertainment of NOTCH3 pathogenic variants
The variants located in the NOTCH3 gene (chromosome 
19:15,159,038-15,200,995, reference genome assembly 
GRCh38) were extracted from the exome data in PLINK format. 
The extracted variants were annotated using Ensembl Variant 
Effect Predictor.14 Missense variants that lead to the gain or loss 
of a cysteine residue in one of the 34 EGFR domains of the 
NOTCH3 protein (amino acid position 40-1373, Uniprot acces-
sion number: Q9UM47) were identified.
Phenotypic data fields
History of vascular risk factors, measured blood pressure, blood 
pressure medication and parental history of stroke were recorded. 
History of diseases, including stroke, vascular dementia, 
epilepsy, depression, migraine and myocardial infarction, were 
determined from self- report, hospital and death records (code 
list in online supplemental table 1). The Framingham cardio-
vascular risk score was calculated.15 Results of cognitive tests,16 
including pairs matching, reaction time, prospective memory, 
fluid intelligence, numeric memory, trail- making test part B and 
the symbol digit substitution test, were extracted and converted 
into z- scores. The average of all z- scores was used as an estimate 
of global cognitive function.17 The following blood tests were 
extracted (cholesterol, low- density lipoprotein, high- density 
lipoprotein (HDL), apolipoprotein A, apolipoprotein B, lipo-
protein A (Lp(a)), triglycerides, glycated haemoglobin, glucose, 
C reactive protein (CRP), creatinine, cystatin C and urea).
Brain imaging analysis
In the 19 686 participants with MRI available, measures were 
compared between variant subjects and controls. UK Biobank 
neuroimaging working group- derived MRI measures for brain 
volume and WMH volume were used, generated by an image- 
processing pipeline developed and run on behalf of UK Biobank.13 
Brain volume was estimated by SIENAX,18 and normalised for 
head size. WMHs were quantified on fluid attenuated inversion 
recovery (FLAIR) images through the brain intensity abnor-
mality classification algorithm.19 Furthermore, the peak width 
skeletonised mean diffusivity (PSMD)20 was derived in- house 
from diffusion tensor imaging (DTI) data and is a marker of 
diffuse white matter damage.19
Additionally, visual review of MRI scans (T1- weighted, T2 
FLAIR and susceptibility- weighted imaging (SWI)) from those 
cases with NOTCH3 variants and MRI available (N=47) was 
performed by a neurologist (SN). Each variant case was matched 
with three controls for age, sex, ethnicity and family history of 
stroke. Scans were analysed blinded to subject identity. Lacunar 
infarcts, cerebral microbleeds, and the spatial distribution and 
extent of WMH were quantified. Lacunes were counted on 
FLAIR images, defined as a round or ovoid subcortical fluid- 
filled cavity of 3–15 mm in diameter in the territory of a single 
perforating arteriole.21 Cerebral microbleeds were counted using 
the brain observer microbleed scale,22 defined as round well- 
defined hypointense foci on SWI with a diameter of 2–10 mm. 
The spatial distribution and extent of WMH in different brain 
regions was quantified on T2 FLAIR images using the modified 
Schelten’s scale.23
Calculation of polygenic risk score
To compare the risk conferred by NOTCH3 variants with that by 
common stroke variants, we calculated an ischaemic stroke poly-
genic risk score (PRS) using more than 3 million common genetic 
variants.24 We performed linear regression of the PRS adjusting 
for the first 10 ancestry principal components in UK Biobank to 
account for known differences in PRS performance across ethnic 
groups.25 Standardised residuals from this regression model were 
used for analyses. We calculated the OR for ischaemic stroke in 
NOTCH3 carriers compared with non- carriers and the OR for a 
1 SD increase in the ischaemic stroke PRS, dividing the former 
by the latter (on the log- scale, assuming a linear association) to 
estimate the increment of the PRS in SD that was predicted to 
be equivalent to the risk conferred by NOTCH3 variants.26 To 
examine whether the ischaemic stroke PRS affected NOTCH3 
penetrance, we performed statistical tests for interaction between 
the PRS and NOTCH3 status; we divided our sample cohort into 
three groups based on their PRS: low (bottom 20% of PRS), 
intermediate and high (top 20%) risk.27
Statistical analysis
The effect of NOTCH3 variants on phenotype was assessed by 
linear regression for continuous outcomes and logistic regres-
sion for binary outcomes. For the former, effect sizes were 
standardised to enable a more informative comparison. Firth’s 
correction was applied to all logistic regression models to account 
for rare event bias.28 All regression models were adjusted for age, 
sex, exome sequencing batch and first 10 principal components 
of ancestry. Any data fields that did not follow a normal distribu-
tion were transformed through: natural log (HDL, triglycerides, 
CRP and WMH), inverse normalisation (Lp(a), Framingham 
cardiovascular risk score and the regional WMH scores) or 
square root (cerebral microbleed and lacune counts). When 
comparing demographic and risk factor profiles between variant 
and non- variant groups, Pearson’s Χ2 test was used for categor-
ical variables and the two- sample t- test was used for continuous 
variables. All statistical analyses were performed using R V.3.6.2 
and Stata V.15.1 with 2- sided p values and p<0.05 for statistical 
significance.
RESULTS
The prevalence of NOTCH3 pathogenic variants
Of the 200 632 participants with exome sequencing data, 
443 (2.2 per 1000) carried NOTCH3 variants leading to an 
unpaired cysteine residue in one of the 34 EGFR domains of 
the NOTCH3 protein. All carriers were heterozygotes, giving 
a population frequency of 1 in 452, about 100- fold higher than 
expected based on CADASIL prevalence estimations of 2–5 in 
100 000.7
Distribution of NOTCH3 pathogenic variants
The distribution of variants is shown in figure 1, online supple-
mental table 2 and online supplemental figure 1. In total, 67 
unique NOTCH3 pathogenic variants were identified, of which 
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36 were observed in only one individual. The identified variants 
were spread across 22 different exons between exons 2 and 24 
of the NOTCH3 gene (except exon 16; figure 1). They affected 
31 EGFR domains, involving all EGFR domains except 7, 21 
and 34. Variants were predominantly located towards the distal 
end of NOTCH3 protein; only 11 participants had a NOTCH3 
variant located in EGFR domains 1–6 (figure 1 and online 
supplemental figure 1). More than half of the variants (39 of 67, 
58.2%) involved the swapping of cysteine and arginine residues.
Sixty- five different variants were found in 378 white partic-
ipants, 3 in 41 individuals of Asian or Asian British ancestry, 3 
in 7 Black or Black British participants, 1 variant in a Chinese 
participant, 1 in 4 mixed ethnicity individuals and 4 in other 
ethnic groups. Ten of the unique variants occurred in non- white 
subjects, and three were not observed in white individuals (p.Cy-
s579Tyr, p.Gly861Cys and p.Cys1250Arg).
NOTCH3 variants were not associated with vascular risk 
factors, blood biochemistry or cognition
The demographic and risk factor profile of cases with and 
without variants are shown in table 1. There were no signifi-
cant differences between groups, except that the variant group 
had more men and less white subjects. NOTCH3 variants were 
not associated with vascular risk factors, blood biochemistry 
markers, the Framingham cardiovascular risk score or cognitive 
function (online supplemental figure 2).
NOTCH3 variant carriers were at an increased risk of stroke 
and vascular dementia
Presence of NOTCH3 variants was associated with a twofold 
increase in the odds of stroke (OR: 2.33, 95% CI: 1.50 to 3.45, 
p=0.0004). Vascular dementia (OR: 5.00, 95% CI: 1.66 to 
11.43, p=0.007) was also more frequent in variant carriers. All 
dementia cases in NOTCH3 carriers were of vascular origin (and 
occurred after enrolment into UK Biobank). All- cause dementia 
was not significantly associated with the presence of NOTCH3 
variants (OR: 2.11, 95% CI: 0.70 to 4.79, p=0.16). Popula-
tion attributable fractions showed that 0.26% of stroke and 
0.72% vascular dementia in UK Biobank were attributed to the 
NOTCH3 variants. There was a borderline significant increase 
in epilepsy (OR:1.92, 95% CI: 1.01 to 3.29, p=0.048). Presence 
of a variant was associated with an increased family history of 
stroke (OR:1.41, 95% CI: 1.06 to 1.85, p=0.02). No signifi-
cant associations were found with migraine (OR: 1.41, 95% CI: 
Figure 1 Lolliplot showing the distribution of distinct pathogenic variants in UK Biobank across the reverse strand of the NOTCH3 gene. Lighter circles 
represent variants without rsID; darker circles represent variants with rsID; lighter rectangular boxes represent exons that encode EGFRs 7–34; darker 
rectangular boxes represent exons that encode EGFRs 1–6. EGFR, epidermal growth factor- like repeat.
Table 1 Comparison of the demographic and risk factor profile for cases with and without NOTCH3 variants
NOTCH3 variant carriers Non-NOTCH3 variant carriers P value
Number of cases 443 200 189
Mean (SD) age at recruitment (years) 55.7 (8.2), range 40–70 56.5 (8.2) range 38–72 0.06
Male sex (%) 223 (50) 89 872 (45) 0.02
White ethnic background (%) 378 (85) 187 912 (94) 1.53×10–15
Mean (SD) BMI (kg/m2) 27.8 (5.0) 27.4 (4.8) 0.12
Non- smoker (%) 399 (90.0) 180 955 (90.4) 0.82
Blood pressure medication (%) 37 (8.4) 20 171 (10.1) 0.23
Hypertension (%) 142 (32.1) 65 361 (32.6) 0.79
Hypercholesterolaemia (%) 49 (11.1) 19 085 (9.5) 0.27
Diabetes mellitus (%) 41 (9.3) 14 257 (7.1) 0.08
The p values for categorical and continuous variables were calculated by the Pearson’s Χ2 test and two- sample t- test, respectively.
BMI, body mass index.
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0.94 to 2.03, p=0.09) or depression (OR: 0.88, 95% CI: 0.56 
to 1.32, p=0.56) (figure 2).
Significant associations were repeated after additional adjust-
ment for diabetes, hypertension and smoking. Results were unal-
tered for vascular dementia (OR: 5.00, 95% CI: 1.66 to 11.48, 
p=0.007), stroke (OR: 2.37, 95% CI: 1.52 to 3.53, p=0.0003) 
and family history of stroke (OR: 1.42, 95% CI: 1.06 to 1.86, 
p=0.02).
The risk of both stroke and vascular dementia was higher with 
variants in EGFRs 1–6 compared with EGFRs 7–34 (figure 3). 
The risk of stroke was 13- fold higher (OR 13.60, 95% CI: 2.46 
to 53.50, p=0.006) and overdouble (OR 2.17, 95% CI: 1.37 to 
3.26, p=0.001) than that of variant- free individuals, respectively, 
for variants in EGFRs 1–6 and 7–34, with findings for vascular 
dementia risk mirroring this.
Similar associations were observed when the same analyses 
were performed for incident cases of outcomes, that is, those that 
had occurred from the point of recruitment into UK Biobank to 
the latest follow- up in March 2019 (online supplemental figure 
3, 4).
NOTCH3 variant carriers showed signs of brain MRI 
abnormalities
NOTCH3 variants were associated with an increase in WMH 
volume (standardised difference: 0.52, 95% CI: 0.29 to 0.75, 
Figure 2 Forest plot showing the association of NOTCH3 variant with different diagnoses. Family history and prevalence of disease cases were analysed 
with the presence of NOTCH3 variant through logistic regression. Firth’s correction was applied to all the regression models. N=200 632. *Significance at 
p<0.05.
Figure 3 Forest plot showing the effect of NOTCH3 variant location on the odds of stroke or vascular dementia. The location of variant was stratified by 
EGFRs 7–34 and EGFRs 1–6; their effect on disease risk was relative to that without the variant. Firth’s correction was applied to all the regression models. 
N=200 632. *Significance at p<0.05. EGFR, epidermal growth factor- like repeat.
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p=9.1×10−6) and DTI- PSMD (standardised difference: 0.72, 
95% CI: 0.39 to 1.03, p=7.0×10−8) but not with brain volume.
MRI scans from 47 NOTCH3 variant carriers and 148 matched 
controls were visually rated and compared (table 2, figure 4 and 
online supplemental figure 5). Image sequences available were 
T1- weighted (47 cases, 148 controls), T2 FLAIR (45 cases, 148 
controls) and SWI (44 cases, 148 controls). NOTCH3 variants 
were associated with an increased risk of the presence of lacunes 
(OR: 5.97, 95% CI: 2.00 to 12.06, p=0.0002) and cerebral 
microbleeds (OR: 4.38, 95% CI: 1.69 to 7.76, p=0.0003). 
There were also significant association with the number of 
lacunes (standardised difference: 0.59, 95% CI: 0.23 to 0.89, 
p=0.0007) and borderline association with the number of cere-
bral microbleeds (standardised difference: 0.37, 95% CI: 0.05 
to 0.74, p=0.046).
NOTCH3 variants were associated with a CADASIL-like 
distribution of WMH
The presence of NOTCH3 variants was correlated with the 
spatial distribution and extent of WMH using the modified 
Schelten’s scale. First, we examined the distribution of the pres-
ence of any WMH in each brain region (table 2). NOTCH3 
variants were most strongly associated with any WMH in two 
areas previously reported to be predilection sites for WMH in 
CADASIL,25 the anterior temporal lobe (OR: 7.65, 95% CI: 
3.14 to 19.81, p<0.001) and external capsule (OR: 13.32, 
95% CI: 4.96 to 39.89, p<0.001). Typical example scans are 
shown in figure 4. Second, we examined the severity of WMH 
in each region, as assessed on the Schelten’s scale. NOTCH3 
variants were associated with higher aggregate WMH score 
(standardised difference: 0.51, 95% CI: 0.24 to 0.84, p=0.001) 
and higher individual scores for 8 of the 17 brain regions exam-
ined, including the periventricular region, frontal lobe, parietal 
lobe, occipital lobe, anterior temporal lobe, caudate, thalamus 
and external capsule (figure 5). Concordantly, the differences 
between variant carriers and non- carriers were most marked 
for the anterior temporal lobe and the external capsule. All 
these associations remained significant after accounting for 
multiple comparisons using a false- discovery rate of 5% with the 
Benjamini- Hochberg procedure.
NOTCH3 associations with ischaemic stroke were 
independent of polygenic risk
NOTCH3 carriers had a threefold increased risk of ischaemic 
stroke (OR 3.07, 95% CI: 1.81 to 5.23, p<0.001), while a 1 
SD increase in ischaemic stroke PRS increased the odds by 26% 
(OR: 1.26, 95% CI: 1.21 to 1.32, p<0.001). We calculated pres-
ence of a NOTCH3 variant therefore conferred the same risk as 
a 4.85 SD increase in PRS (figure 6). Conscious of substantial 
uncertainty in our estimated association for NOTCH3 status 
and ischaemic stroke, we calculated more conservative estimates 
using the lower bound of 95% CI for NOTCH3 with the OR 
(conservative NOTCH3) as well as upper bound of the 95% 
CI for the association with the PRS (most conservative). These 
Table 2 Comparison of WMH distribution on the modified Schelten’s scale between NOTCH3 variant carriers and non- carriers
Brain regions
Number (%) of non- carrier 
cases Number (%) of mutation cases OR (95% CI) P value
Periventricular white matter 108 (73) 36 (80) 1.51 (0.65 to 3.88) 0.34
Frontal white matter 119 (80) 40 (89) 1.40 (0.50 to 4.57) 0.53
Parietal white matter 79 (53) 34 (76) 2.44 (1.11 to 5.68) 0.03
Occipital white matter 45 (30) 20 (44) 1.82 (0.88 to 3.80) 0.11
Anterior temporal white matter 12 (9) 17 (38) 7.65 (3.14 to 19.81) <0.001
Posterior temporal white matter 45 (30) 14 (31) 0.94 (0.42 to 2.03) 0.87
Corpus callosum 7 (5) 5 (11) 2.34 (0.65 to 7.95) 0.18
Caudate 1 (1) 3 (7) 7.80 (1.30 to 72.60) 0.03
Putamen 16 (11) 9 (20) 1.97 (0.77 to 4.88) 0.15
Globus pallidus 4 (3) 0 (0) 0.19 (0.00 to 2.13) 0.21
Thalamus 4 (3) 6 (13) 3.90 (1.05 to 14.91) 0.04
Internal capsule 3 (2) 2 (4) 2.20 (0.35 to 11.12) 0.37
External capsule 9 (6) 17 (38) 13.32 (4.96 to 39.89) <0.001
Cerebellum 4 (3) 3 (7) 2.10 (0.43 to 8.91) 0.34
Mesencephalon 3 (2) 2 (4) 3.84 (0.57 to 27.84) 0.16
Pons 25 (17) 11 (24) 1.51 (0.64 to 3.46) 0.34
Medulla 2 (1) 0 (0) 0.80 (0.01 to 8.86) 0.87
Table showing the effect of the presence of NOTCH3 variants on the odds of developing any WMH in each brain region.
WMH, white matter hyperintensity.
Figure 4 Axial T2 FLAIR brain MRI of two subjects with a pathogenic 
NOTCH3 variant in UK Biobank. (A) A woman in her 50s, carrying a 
p.Arg1231Cys variant that affects EGFR domain 31, with WMH involving 
the right anterior temporal lobe (arrow). (B) A man in his 60s, carrying a 
p.Arg578Cys variant that affects EGFR domain 14, with WMH involving 
the external capsule bilaterally (arrows). EGFR, epidermal growth factor- 
like repeat; FLAIR, fluid attenuated inversion recovery; WMH, white matter 
hyperintensity.
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placed carriers of NOTCH3 variants as having a polygenic risk 
equivalent to the upper 1.5% of the population. We observed 
no interaction between NOTCH3 carrier status and PRS (online 
supplemental figure 6).
DISCUSSION
In this study of 200 632 individuals, we show that NOTCH3 
variants are much more common than expected in the general 
population, being present in 1 in 450 individuals. We demon-
strated that these ‘asymptomatic’ variants are associated with an 
increased risk of both stroke and vascular dementia, and with 
MRI features of SVD, including lacunar infarcts, WMH, diffuse 
white matter damage on DTI and cerebral microbleeds. Taken 
together, these results suggest that typical CADASIL variants are 
common in the general population, and account for a significant 
burden of apparently ‘sporadic’ stroke and dementia.
CADASIL is reported to be rare, with an estimated disease 
prevalence of 4 per 100 000 individuals in UK populations.5 6 In 
contrast, recent studies have demonstrated an increased frequency 
of cysteine- changing NOTCH3 variants in population data-
bases,7 9 but these have been anonymised databases making it 
impossible to determine whether these variants associate with 
clinical disease. A recent report from the US Geisinger database 
suggested NOTCH3 variants are associated with an increased 
risk of stroke and MRI features of SVD, although no associa-
tion was found with dementia.8 Our findings are broadly confir-
matory of those in the Geisinger cohort although we reported 
a slightly higher prevalence of NOTCH3 variants (0.22% vs 
0.14%) and our larger sample size also allowed an association 
with vascular dementia to be detected.
Our findings provide robust evidence from a large 
population- based study of over 200 000 individuals that 
common NOTCH3 variants are associated with symptomatic 
cerebrovascular disease in the general population. We demon-
strated that they conferred a risk equivalent to that in the top 
1.5% of individuals as determined by a PRS, with the risks 
from common polygenic variant and NOTCH3 variants being 
independent. Of note, the contribution of variants causing 
familial stroke to the risk of common stroke is being increas-
ingly recognised, not only in the context of CADASIL, but for 
example in moyamoya disease.29
In addition to an association with stroke, we demonstrate a 
strong association with vascular dementia. All cases of dementia 
occurring in patients with NOTCH3 variants were of a vascular 
origin; no association was found with all- cause dementia, 
reflecting the fact that many cases of dementia in older individ-
uals are due to non- vascular pathologies. We also found trends 
towards other clinical features of CADASIL being more common 
with these variants with a marginally significant association with 
epilepsy, and a non- significant trend towards increased risk of 
migraine.
In addition to looking at overall brain MRI measures, we 
analysed the distribution of white matter lesions in individuals 
with NOTCH3 variants, compared with matched controls. The 
greatest increase in WMH was in two areas known to be partic-
ularly affected in CADASIL, namely the anterior temporal lobes 
and external capsule.30 This suggests that the NOTCH3 variants 
are not merely associated with stroke, but also with a specific 
CADASIL- like phenotype in the general population. Although 
the phenotype of the variant carriers is much milder in the UK 
Figure 5 Forest plot showing the severity of WMH in different brain regions. Inversely transformed measures of the Schelten’s scale were analysed with 
the presence of NOTCH3 variant through linear regression. A total of 193 participants were included in the regression analyses, of which 45 were variant 
carriers and 148 were non- carriers. *Significance p<0.05. WM, white matter; WMH, white matter hyperintensity.
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Biobank cohort, the distribution of white matter changes is 
similar to that seen in patients with CADASIL.
It remains uncertain why some patients with NOTCH3 vari-
ants develop the CADASIL phenotype, while others appear 
asymptomatic. One emerging factor is variant position. Within 
CADASIL cohorts, variants in EGFRs 1–6 have been associ-
ated with earlier stroke onset than variants in EGFRs 7–34.10 
In previous population studies, variants in EGFRs 7–34 were 
much more common,10 and we confirmed this in UK Biobank. 
Furthermore, we found that although variants in EGFRs 1–6 
were associated with higher risk of stroke and vascular dementia 
in the general population, more distal variants in EGFRs 7–34 
were still associated with risk of both conditions. CADASIL vari-
ants alter the extracellular domain of NOTCH3 (Notch3ECD) 
resulting in its multimerisation and aberrant accumulation in 
granular osmiophilic material.31 The mutant Notch3ECD facili-
tates interactions with components of the cerebrovascular extra-
cellular matrix, including the metalloproteinase inhibitor TIMP3 
and vitronectin, and promotes their accumulation and seques-
tration in Notch3ECD- containing deposits. How this process is 
affected by NOTCH3 pathogenic variant position is unclear; it 
could result from differences in the expression, processing, inter-
action and aggregation properties of mutant NOTCH3. None-
theless, variant site fails to account for much of the phenotypic 
heterogeneity. Vascular risk factors, particularly smoking and 
hypertension, have been shown to be associated with an earlier 
onset of stroke within CADASIL families but only account for 
a small amount of variability.32 33 Family studies have suggested 
that as much of 60% of the heritability of WMH lesion volume 
is accounted for by yet undetermined modifier genetic factors 
outside the NOTCH3 gene, but the nature of these remains 
undetermined.34
Our study has a number of strengths. First, it included data 
from over 200 000 individuals with exome sequencing. Second, 
we correlated the genotyping with extensive clinical informa-
tion, including prospectively collected information obtained 
from linked electronic health records. This allowed us to identify 
associations not only with disease prevalence but also incident 
disease occurring during prospective follow- up. This revealed 
similar associations with stroke and vascular dementia to that 
observed in the prevalence data. Third, all scans had been 
performed on one of the two identical MR scanners using iden-
tical sequences improving consistency and quality.
Our study also has limitations. Diseases like dementia can 
sometimes be misclassified or under- represented by the ICD 
codes in health records. Our analysis was in predominantly 
white populations. CADASIL has been shown to be present in 
all ethnic groups in which it is being looked for, and we have 
no reason to suspect the associations reported are different in 
other ethnic groups. However, frequency of NOTCH3 variants 
may differ between ethnic groups, and initial data suggest that 
it is higher in Far Eastern populations including Taiwan.35 Perti-
nently, a recent report suggested typical CADASIL variants may 
predispose to multifactorial late- onset stroke in Taiwan.36
In conclusion, our study shows that typical cysteine- changing 
NOTCH3 variants are common in the general population and 
these variants are associated with increased risk of both stroke 
and vascular dementia, and with MRI markers of SVD including 
WMH and lacunar infarcts. This demonstrates that genetic 
variation in the NOTCH3 gene accounts for a much greater 
proportion of stroke in the general population than previously 
thought. Although the magnitude of risk for a NOTCH3 variant 
on stroke and vascular dementia partly depends on variant site, 
modifiers outside the NOTCH3 gene appear to be important. 
Figure 6 Estimated polygenic risk equivalent for the association of NOTCH3 status with ischaemic stroke. Average=ratio of the log- OR of models of 
NOTCH3 status and a 1 SD increase in polygenic risk score (PRS) for ischaemic stroke; conservative NOTCH3=ratio of the lower 95% CI of the log- OR for 
NOTCH3 status and the log- OR for a 1 SD increase in PRS for ischaemic stroke; most conservative=ratio of the lower 95% CI of the log- OR for NOTCH3 
status and the upper 95% CI of the log- OR for a 1 SD increase in PRS for ischaemic stroke. Population percentages calculated using a 1- sided z- score.
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Further research is required to identify these. Finally, our study 
emphasises that the boundaries between monogenic and poly-
genic stroke are not as distinct as previously believed.
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